The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices

Cost Effectiveness and Resource Allocation

Volumn 11, Issue 1, 2013, Pages

  Vogler, Sabine ^a   Zimmermann, Nina ^a   Habl, Claudia ^a   Mazag, Jan ^b  

^a GESUNDHEIT ÖSTERREICH GMBH   (Austria)

^b State Institute of Drug Control   (Slovakia)

Author keywords

Austria; Cost free medicines; Discount; Hospital; Medicine prices; Pharmaceutical policy

Indexed keywords

AMLODIPINE; ATORVASTATIN; CLOPIDOGREL; DOCETAXEL; ETANERCEPT; IMATINIB; IMMUNOGLOBULIN; INFLIXIMAB; PEGINTERFERON BETA1A; RITUXIMAB; SIMVASTATIN; TRASTUZUMAB;

ARTICLE; GENERAL HOSPITAL; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH SURVEY; HOSPITAL COST; HOSPITAL PHARMACY; MULTIPLE SCLEROSIS; OUTPATIENT DEPARTMENT; QUESTIONNAIRE; REIMBURSEMENT;

EID: 84879833817     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-11-15     Document Type: Article

References (50)

1. Espin J, Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe 2007, Brussels: DG Enterprise and Industry of the European Commission.
2. Vogler S, Espin J, Habl C. Pharmaceutical Pricing and Reimbursement Information (PPRI) - New PPRI analysis including Spain. Pharmaceuticals Policy and Law 2009, 11:213-234.
3. Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M. Differences in costs of and access to pharmaceutical products in the EU 2011, Brussels: European Parliament.
4. Dukes MNG, Haaijer-Ruskamp FM, de Joncheere CP, Rietveld AH. Drugs and Money. Prices, affordability and cost containment 2003, Amsterdam, Berlin, Oxford, Tokyo, Washington DC: World Health Organization, 7.
5. Vogler S, Habl C, Bogut M, Voncina L. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croat Med J 2011, 52:197.
6. Vogler S, Habl C, Leopold C, Rosian-Schikuta I. PPRI Report 2008, Vienna: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG.
7. Drummond M, Jonsson B, Rutten F, Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur J Health Econ 2011, 12:263-271. 10.1007/s10198-010-0274-y, 3078322, 20803050.
8. Vogler S, Zimmermann N, Mazag J. Procuring medicines in hospitals: results of the European PHIS survey. EJHP Practice 2011, 2:20-21.
9. Scheuringer M, Sahakyan N, Krobot K, Ulrich V. Cost of clinical events in health economic evaluations in Germany: a systematic review. Cost Eff Resour Alloc 2012, 10:7. 10.1186/1478-7547-10-7, 3495193, 22651885.
10. Azoulay A, Doris N, Filion K, Caron J, Pilote L, Eisenberg M. The use of the transition cost accounting system in health services research. Cost Eff Resour Alloc 2007, 5:11. 10.1186/1478-7547-5-11, 2000458, 17686148.
11. Tarricone R, Torbica A, Franzetti F, Rosenthal V. Hospital costs of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy. Cost Eff Resour Alloc 2010, 8:8. 10.1186/1478-7547-8-8, 2889855, 20459753.
12. Geitona M, Hatzikou M, Hatzistamatiou Z, Anastasiadou A, Theodoratou T. The economic burden of treating neonates in Intensive Care Units (ICUs) in Greece. Cost Eff Resour Alloc 2007, 5:9. 10.1186/1478-7547-5-9, 1939832, 17634126.
13. Adam T, Evans D, Murray C. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 2003, 1:3. 10.1186/1478-7547-1-3, 156022, 12773218.
14. Perren A, Donghi D, Marone C, Cerutti B. Economic burden of unjustified medications at hospital discharge. Swiss Med Wkly 2009, 139:430-435.
15. Vogler S, Habl C, Leopold C, Mazag J, Morak S, Zimmermann N. PHIS Hospital Pharma Report 2010, Vienna: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG.
16. Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther 2005, 21:1203-1209. 10.1111/j.1365-2036.2005.02454.x, 15882240.
17. Gallini A, Legal R, Taboulet F. The influence of drug use in university hospitals on the pharmaceutical consumption in their surrounding communities. Br J Clin Pharmacol 2012, 7:1365-2125.
18. Feely J, Chan R, McManus J, O'Shea B. The influence of hospital-based prescribers on prescribing in general practice. Pharmacoeconomics 1999, 16:175-181. 10.2165/00019053-199916020-00006, 10539398.
19. Prosser H, Almond S, Walley T. Influences on GPs' decision to prescribe new drugs-the importance of who says what. Fam Pract 2003, 20:61-68. 10.1093/fampra/20.1.61, 12509373.
20. Schröder-Bernhardi D, Dietlein G. Lipid-lowering therapy: do hospitals influence the prescribing behavior of general practitioners?. Int J Clin Pharmacol Ther 2002, 40:317-321.
21. Grimmsmann T, Schwabe U, Himmel W. The influence of hospitalisation on drug prescription in primary care-a large-scale follow-up study. Eur J Clin Pharmacol 2007, 63:783-790. 10.1007/s00228-007-0325-1, 17549465.
22. Habl C, Leopold C, Morak S. PPRI Pharma Profile Austria 2008, Vienna: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG.
23. Bucsics A. Current issues in drug reimbursement. Clinical Pharmacology: Current Topics and Case Studies 2010, 33-50. Vienna: Springer, Müller M.
24. Zimmermann N, Vogler S. PHIS Hospital Pharma Report Austria 2009, Vienna: Gesundheit Österreich GmbH / Geschäftsbereich ÖBIG.
25. Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res 2008, 8:357-371. 10.1586/14737167.8.4.357, 20528343.
26. Kanavos P, Schurer W, Vogler S. Pharmaceutical Distribution Chain in the European Union: Structure and Impact on Pharmaceutical Prices 2011, London/Vienna: EMINet.
27. The Council of European Communities Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems 1989, Brussels, The Council of European Communities.
28. OECD Pharmaceutical pricing policies in a global market 2008, Paris: OECD, OECD.
29. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009, 373:240-249. 10.1016/S0140-6736(08)61762-6, 19042012.
30. Brekke KR, Holmås TH, Straume OR. Are Pharmaceuticals Still Inexpensive in Norway? A Comparison of Prescription Drug Prices in Ten European Countries. SNF report no. 08/10 2010, Bergen: SNF.
31. Danzon PM, Chao LW. Cross-national price differences for pharmaceuticals: how large, and why?. J Health Econ 2000, 19:159-195. 10.1016/S0167-6296(99)00039-9, 10947575.
32. Walter E, Batista A, Brennig C, Zehetmayr S. Der österreichische Pharmamarkt - ein europäischer Vergleich 2008, Vienna: Institut für Pharmaökonomische Forschung.
33. Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R. Differences in external price referencing in Europe-A descriptive overview. Health Policy 2012, 104:50-60. 10.1016/j.healthpol.2011.09.008, 22014843.
34. General Social Insurance Act § 351c, Federal Law No. 189/1955, latest change by Federal Law I No. 398/2011 [in German] 2012, Vienna: Republic of Austria.
35. Bundesministerium für Gesundheit Regelung für die Vorgehensweise der Preiskommission bei der Ermittlung des EU-Durchschnittspreises gemäß § 351c Abs. 6 ASVG 2008, Vienna: Austrian Federal Ministry of Health, Bundesministerium für Gesundheit.
36. Hoebert J, Mantel-Teuwisse A. Pharmaceutical Health Information (PHIS) Evaluation Report 2011, Utrecht: Utrecht WHO Collaborating Centre for Pharmacoepidemiology and Pharmaceutical Policy.
37. Glossary of pharmaceutical terms http://whocc.goeg.at/Glossary/Search.
38. Aanes T, Ognøy AH, Festøy H. PHIS Hospital Pharma Report Norway 2009, Vienna: Pharmaceutical Health Information System (PHIS).
39. Caldeira S, Furtado C, Vieira I, Baptista A. PHIS Hospital Pharma Report Portugal 2010, Vienna: Pharmaceutical Health Information System (PHIS).
40. Mazag J. PHIS Hospital Pharma Report Slovakia 2009, Vienna: Pharmaceutical Health Information System (PHIS).
41. Storms H, Schreurs M. PHIS Hospital Pharma Report The Netherlands 2010, Vienna: Pharmaceutical Health Information System (PHIS).
42. WHO Health Action International (HAI). Measuring medicine prices, availability, affordability and price components 2008, Geneva, 2, WHO.
43. Andre G, Semerdjiev I. PHIS Hospital Pharma Report Bulgaria 2009, Vienna: Pharmaceutical Health Information System (PHIS).
44. Schwappach D, Boluarte T, Suhrcke M. The economics of primary prevention of cardiovascular disease - a systematic review of economic evaluations. Cost Eff Resour Alloc 2007, 5:5. 10.1186/1478-7547-5-5, 1876202, 17501999.
45. Hauptverband der österreichischen Sozialversicherungsträger Statistisches Handbuch der österreichisschen Sozialversicherung 2009 2009, Wien: Hauptverband der österreichischen Sozialversicherungsträger, Hauptverband der österreichischen Sozialversicherungsträger.
46. de Vries CS, van Diepen NM, Tromp TF, den Berg LT DJV. Auditing GPs' prescribing habits: cardiovascular prescribing frequently continues medication initiated by specialists. Eur J Clin Pharmacol 1996, 50:349-352. 10.1007/s002280050121, 8839654.
47. Langebner T. Managing drug costs in Austria. EJHP Practice 2007, 13:79.
48. Wikler D. Why prioritize when there isn't enough money?. Cost Eff Resour Alloc 2003, 1:5. 10.1186/1478-7547-1-5, 156024, 12773216.
49. Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, Hasselström J, Hensjö L-O, Hjemdahl P, Jägre I, Julander M, et al. The 'Wise List'- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm. Basic Clin Pharmacol Toxicol 2011, 108:224-233. 10.1111/j.1742-7843.2011.00682.x, 21414143.
50. Herms S, Rutledge P. The Lothian Joint Formulary: overcoming the barriers to formulary success. Pharma Prac 2002, 12:279-285.